Cytogen retains the rights to manufacture and use PSMA for all other indications. PSMA is an antigen that is highly expressed in malignant prostate cancer cells, thus making it a putative target upon which to direct the body's immune system against the cancer. For example, beginning in 2001, together with our partner Progenics Pharmaceuticals, we plan to begin a series of in vivo immunotherapy clinical studies of a prostate cancer vaccine and of monoclonal antibodies for the treatment of prostate cancer. We believe that both the ex vivo and in vivo approaches will offer prostate cancer patients important, promising new therapies that are designed to marshal the patients' immune system against his cancer.
Prostate cancer is the most common cancer among American males, second only to skin cancer.
Prohost is an independent publication providing information on biotech companies. Prohost does not accept compensation from companies that are featured or profiled. It is strongly recommended that any purchase or sale decisions to any of the featured companies be discussed with a financial advisor or broker prior to completing any such purchase or sale decision. All statements or expressions are the opinion of Prohost and are not meant to be a solicitation or recommendation to buy, sell, or hold securities. Investing in embryonic companies, micro-cap and growth securities is highly speculative and carries a high degree of risk.